BAY 60-7550

Name	Bay 60-7550
Synonyms	BAY 607550 BAY 60-7550 Bay 60-7550 2-(3,4-Dimethoxybenzyl)-7-((2R,3R)-2-hydroxy-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f][1,2,4] 2-[(3,4-Dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-imidazo[5,1-f][1,2,4]triazin-4(1H)-one Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[(3,4-dimethoxyphenyl)methyl]-7-[(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl]-5-methyl-
CAS	439083-90-6

Molecular Formula	C27H32N4O4
Molar Mass	476.57
Density	1.24±0.1 g/cm3(Predicted)
Boling Point	680.7±65.0 °C(Predicted)
Appearance	powder
Color	white to light brown
pKa	14.54±0.20(Predicted)
Storage Condition	-20°C
In vitro study	Bay 60-7550 (1 μM) increases cGMP in the neuronal cultures compared with control [F(6,14)=12.97, p<0.05 for Bay 60-7550]. Bay 60-7550 in the presence of NMDA (30 μM) results in further increases in cGMP compared with NMDA alone. The NMDA receptor antagonist MK-801 (10 μM) blocks both Bay 60-7550+NMDA-induced elevation in cGMP in neuronal cultures. Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1 μM).
In vivo study	The PDE2 inhibitors Bay 60-7550 (1 mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle + restraint stress condition. In nonstressed mice, Bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3 mg/kg. In nonstressed mice, Bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared with vehicle-treated mice; significant increases are observed at doses of 1 and 3 mg/kg.

Last Update：2024-01-02 23:10:35

biological activity	Bay 60-7550 is an effective and selective PDE2 inhibitor with a Ki value of 3.8 nM.
target	Ki: 3.8±0.2 nM (PDE2)
in vitro study	Bay 60-7550 (1 μM) increases cGMP in the neuronal cultures compared with control [F(6,14)= 12.97, P <0.05 for Bay 60-7550]. Bay 60-7550 in the presence of NMDA (30 μ M) results in further increases in cGMP compared with NMDA alone. The NMDA receptor antagonist MK-801 (10 μ M) Blocks Both Bay 60-7550 NMDA-induced elevation in cGMP in neuronal cultures. Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1 μM).
in vivo study	The PDE2 inhibitors Bay 60-7550 (1 mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle restraint stress condition. In nonstressed mice, bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3 mg/kg. in nonstressed mice, bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time span head-dipping, compared with vehicle-treated mice; significant increases are observed at doses of 1 and 3 mg/kg.

Last Update：2024-04-09 21:31:59

Product Name: Bay 60-7550 Visit Supplier Webpage Request for quotation
CAS: 439083-90-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: Bay 60-7550 Visit Supplier Webpage Request for quotation
CAS: 439083-90-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

BAY 60-7550

BAY 60-7550 Request for Quotation